Crossref
332 Trends in Prescribing and Costs of Topical Ruxolitinib Among U.S. Dermatologists
Journal of Investigative Dermatology · 2025-11 · 145 (11) · e84
DOI: 10.1016/j.jid.2025.09.334 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Investigative Dermatology, 2025-11. Verfasst von Joshua Kent und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Kent, J., Malave, G. S., Sacknovitz, Y., & Geskin, L. (2025). 332 Trends in Prescribing and Costs of Topical Ruxolitinib Among U.S. Dermatologists. Journal of Investigative Dermatology, 145(11), e84. https://doi.org/10.1016/j.jid.2025.09.334
Vancouver
Kent J, Malave GS, Sacknovitz Y, Geskin L. 332 Trends in Prescribing and Costs of Topical Ruxolitinib Among U.S. Dermatologists. Journal of Investigative Dermatology. 2025;145(11):e84. doi:10.1016/j.jid.2025.09.334
BibTeX
@article{Kent2025,
author = {Kent, Joshua and Malave, Gabriel Santos and Sacknovitz, Yoni and Geskin, Larisa},
title = {332 Trends in Prescribing and Costs of Topical Ruxolitinib Among U.S. Dermatologists},
journal = {Journal of Investigative Dermatology},
year = {2025},
volume = {145},
number = {11},
pages = {e84},
doi = {10.1016/j.jid.2025.09.334}
}
EUVIMED